Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 5.6a

Immunosuppression Use for Induction, 2000 to 2009

Recipients with Kidney Transplants

  Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Transplants 13,620 14,276 14,779 15,137 16,006 16,483 17,095 16,634 16,521 16,830
With Immunosuppression Info 13,257 14,130 14,600 14,938 15,735 16,089 16,740 16,260 16,291 16,546
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 3.2% 2.5% 1.9% 1.1% 1.8% 1.6% 0.6% 1.1% 1.5% 1.5%
OKT3 1.8% 0.8% 0.9% 0.4% 0.3% 0.4% 1.1% 1.2% 1.1% 1.2%
Thymoglobulin 10.1% 17.1% 25.8% 33.6% 36.6% 38.9% 42.1% 43.7% 45.1% 47.5%
Zenapax 13.1% 14.4% 12.9% 12.5% 11.3% 11.6% 11.3% 10.8% 11.2% 10.1%
Simulect 26.6% 25.3% 26.4% 21.6% 19.0% 16.3% 17.8% 16.6% 17.7% 15.7%
Campath 0.0% 0.0% 0.0% 3.6% 6.8% 8.9% 10.3% 9.8% 11.6% 12.8%
No Induction Drugs Recorded 47.7% 42.5% 35.1% 30.2% 27.9% 26.1% 21.2% 21.8% 17.1% 16.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.